All In Biotech

Drug Trial Radar · NCT06939296

A Research Study of VCT220 in Adult Chinese Participants With Obesity

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of VCT220 Tablets in Overweight or Obese Participants

Last checked: Nov 19, 2026Latest source record: Sep 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 840 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

840

Actual

Start

Dec 24, 2024

Primary completion

Nov 25, 2025

Study completion Mar 31, 2026

Sponsor

Lead sponsor
Vincentage Pharma Co., LtdIndustry
Sponsor type
Industry
First posted
Apr 22, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main purpose of this study is to assess how VCT220 tablets affect the bodyweight in obese or overweight adult participants. Participant will be randomly assigned to the high-dose group, low-dose group, or placebo group. Each participant will take the study drug orally once daily for 12 months.

Conditions

  • Obesity
  • Overweight

Interventions

  • VCT220Drug

    A small molecule GLP-1R drug, film coated tablet

  • PlaceboDrug

    Placebo tablets

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage change from baseline in body weightTime frame: From baseline to week 34
  2. The proportion of subjects with a body weight reduction ≥5% from baselineTime frame: From baseline to week 34

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Peking University People's Hospital ( There are multiple sites in this clinical trial)

    Beijing, Beijing Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.